S E Sartorius

2.9k citations

26 papers · 2.4k indexed · h-index 19

Impact in

Oncology top 1%
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Neutropenia and Cancer Infections
- Colorectal Cancer Treatments and Studies
Reproductive Medicine top 5%
- Ovarian cancer diagnosis and treatment

Papers in

Oncology 25
- Cancer Treatment and Pharmacology 13
- Neutropenia and Cancer Infections 7
- Colorectal Cancer Treatments and Studies 7
- Lung Cancer Research Studies 5
- Pancreatic and Hepatic Oncology Research 2
Dermatology 4
- Chemotherapy-related skin toxicity 4

Co-authors: Eric K. Rowinsky Ross C. Donehower L B Grochow Barbara G. Lubejko David S. Ettinger Arlene A. Forastiere Vinay Chaudhry William P. McGuire
Journals: Journal of Clinical Oncology (10 papers)Cancer Chemotherapy and Pharmacology (2 papers)JNCI Journal of the National Cancer Institute (1 paper)Investigational New Drugs (1 paper)Lung Cancer (1 paper)
Partner nations: United States

In The Last Decade

S E Sartorius

26 papers receiving 2.3k citations

Peers

Countries citing papers authored by S E Sartorius

Since Specialization

Citations

This map shows the geographic impact of S E Sartorius's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S E Sartorius with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S E Sartorius more than expected).

Fields of papers citing papers by S E Sartorius

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S E Sartorius. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S E Sartorius. The network helps show where S E Sartorius may publish in the future.

Co-authorship network

The 25 scholars most cited alongside S E Sartorius, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with S E Sartorius Line = papers co-authored together S E Sartorius links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer Cancer Investigation ·Elizabeth Claire Dees, Séamus O’Reilly, Steven N. Goodman, S E Sartorius, Marshall Levine, Richard J. Jones, Louise B. Grochow, Ross C. Donehower, John H. Fetting	2000	131
2	Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator Eniluracil Journal of Clinical Oncology ·Sharyn D. Baker, Robert B. Diasio, Séamus O’Reilly, Virginie Lucas, Manuchi Dansa, S E Sartorius, Ross C. Donehower, Louise B. Grochow, Thomas Spector, John Hohneker, Eric K. Rowinsky	2000	57
3	Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. PubMed ·Sharyn D. Baker, Mark Wirth, Paul Statkevich, Pascale Reidenberg, Kevin B. Alton, S E Sartorius, Margaret Dugan, David L. Cutler, Vijay Batra, Louise B. Grochow, Ross C. Donehower, Eric K. Rowinsky	1999	194
4	A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion Annals of Oncology ·Séamus O’Reilly, Sharyn D. Baker, S E Sartorius, Eric K. Rowinsky, Kathleen M. Fernando, Gregory M. Lubiniecki, L B Grochow, John Gray, Джульетта Вячеславовна Михайлова, Ross C. Donehower	1998	17
5	Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer Investigational New Drugs ·Eric K. Rowinsky, William A. Flood, S E Sartorius, BY DAVIS MURRAY LYON, David S. Ettinger	1997	31
6	Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. Journal of Clinical Oncology ·Eric K. Rowinsky, L B Grochow, S E Sartorius, M K Bowling, Scott H. Kaufmann, David M. Peereboom, Ross C. Donehower	1996	41
7	Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. Journal of Clinical Oncology ·Esther M. John, Marianna Zahurak, Ross C. Donehower, D A Noe, S E Sartorius, H. Fahrländer, BY DAVIS MURRAY LYON, Eric K. Rowinsky	1996	44
8	Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. Journal of Clinical Oncology ·Sharyn D. Baker, S P Khor, Alex A. Adjei, M Doucette, T Spector, Ross C. Donehower, L B Grochow, S E Sartorius, D A Noe, John Hohneker, Eric K. Rowinsky	1996	117
9	The effects of food and divided dosing on the bioavailability of oral vinorelbine Cancer Chemotherapy and Pharmacology ·Eric K. Rowinsky, Virginie Lucas, Gabriela Breda, William A. Wargin, John Hohneker, Barbara G. Lubejko, S E Sartorius, Ross C. Donehower	1996	11
10	Phase I and pharmacologic study of topotecan in patients with impaired renal function. Journal of Clinical Oncology ·Séamus O’Reilly, Eric K. Rowinsky, William J. Slichenmyer, Ross C. Donehower, Arlene A. Forastiere, David S. Ettinger, Z. V. Shukelo, S E Sartorius, L B Grochow	1996	93
11	Phase I and Pharmacologic Studies of Topotecan in Patients With Impaired Hepatic Function JNCI Journal of the National Cancer Institute ·Séamus O’Reilly, Eric K. Rowinsky, William J. Slichenmyer, Ross C. Donehower, Arlene A. Forastiere, David S. Ettinger, H Berzy, S E Sartorius, BY DAVIS MURRAY LYON, James R. Smith, Aleah L. Brubaker, Barbara G. Lubejko, Jennifer Moitoza, L B Grochow	1996	56
12	Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. Journal of Clinical Oncology ·Eric K. Rowinsky, Scott H. Kaufmann, Sharyn D. Baker, L B Grochow, Z. V. Shukelo, David M. Peereboom, M K Bowling, S E Sartorius, David S. Ettinger, Arlene A. Forastiere, Ross C. Donehower	1996	122
13	Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. Journal of Clinical Oncology ·Eric K. Rowinsky, D A Noe, D L Trump, Eric P. Winer, Virginie Lucas, William A. Wargin, John Hohneker, Barbara G. Lubejko, S E Sartorius, David S. Ettinger	1994	52
14	Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies Annals of Neurology ·Vinay Chaudhry, Eric K. Rowinsky, S E Sartorius, Ross C. Donehower, David R. Cornblath	1994	287
15	Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: Hepatotoxicity is dose limiting in humans Lung Cancer ·Eric K. Rowinsky, Dennis A. Noe, David S. Ettinger, Michaele C. Christian, Barbara G. Lubejko, Elliot K. Fishman, S E Sartorius, M. R. Boyd, Ross C. Donehower	1994	41
16	Nursing considerations in paclitaxel (Taxol) administration. PubMed ·Barbara G. Lubejko, S E Sartorius	1993	12
17	Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. Journal of Clinical Oncology ·Eric K. Rowinsky, Vinay Chaudhry, Arlene A. Forastiere, S E Sartorius, David S. Ettinger, L B Grochow, Barbara G. Lubejko, David R. Cornblath, Ross C. Donehower	1993	157
18	Multiple systems organ failure in the patient with cancer. Part I: pathophysiologic perspectives. PubMed ·A. Artikov, S E Sartorius	1992	4
19	Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of Clinical Oncology ·Eric K. Rowinsky, L B Grochow, Carolyn B. Hendricks, David S. Ettinger, Arlene A. Forastiere, Ю Ю Силина, William P. McGuire, S E Sartorius, Barbara G. Lubejko, Scott H. Kaufmann	1992	302
20	Sequences of taxol and cisplatin: a phase I and pharmacologic study. Journal of Clinical Oncology ·Eric K. Rowinsky, Mark R. Gilbert, William P. McGuire, D A Noe, L B Grochow, Arlene A. Forastiere, David S. Ettinger, Barbara G. Lubejko, Bernard J. Clark, S E Sartorius	1991	365

About S E Sartorius

S E Sartorius is a scholar working on Oncology, Dermatology, Neurology, Cancer Research and Hepatology, having authored 26 papers that have together received 2.4k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (13 papers), Cancer therapeutics and mechanisms (11 papers), Neutropenia and Cancer Infections (7 papers), Colorectal Cancer Treatments and Studies (7 papers), Neuroblastoma Research and Treatments (5 papers), Lung Cancer Research Studies (5 papers), Chemotherapy-related skin toxicity (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). The work is most often cited by research in Oncology (1.8k citations), Reproductive Medicine (209 citations), Dermatology (217 citations), Genetics (183 citations) and Hematology (182 citations). S E Sartorius has collaborated with scholars based in United States. Frequent co-authors include Eric K. Rowinsky, Ross C. Donehower, L B Grochow, Barbara G. Lubejko, David S. Ettinger, Arlene A. Forastiere, Vinay Chaudhry, William P. McGuire, D A Noe and David R. Cornblath. Their work appears in journals such as Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, JNCI Journal of the National Cancer Institute, Investigational New Drugs and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact